Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B
HLA Janssen, MR Brunetto, YJ Kim, C Ferrari… - Journal of …, 2018 - Elsevier
Background & Aims Vesatolimod (GS-9620) is an oral agonist of toll-like receptor 7, an
activator of innate and adaptive immune responses. Herein the safety and efficacy of
vesatolimod is assessed after once-weekly treatment in patients with chronic hepatitis B
(CHB) infection suppressed on oral antiviral treatment. Methods In a phase II, double-blind,
randomized, placebo (PBO)-controlled study, 162 patients stratified by hepatitis B surface
antigen (HBsAg) levels and serum hepatitis B e antigen (HBeAg) status were randomized 1 …
activator of innate and adaptive immune responses. Herein the safety and efficacy of
vesatolimod is assessed after once-weekly treatment in patients with chronic hepatitis B
(CHB) infection suppressed on oral antiviral treatment. Methods In a phase II, double-blind,
randomized, placebo (PBO)-controlled study, 162 patients stratified by hepatitis B surface
antigen (HBsAg) levels and serum hepatitis B e antigen (HBeAg) status were randomized 1 …
